They started as simple claims processors. Then, over three decades of mergers and shifts in business strategy, pharmacy benefit managers emerged as powerful conglomerates with the ability to extract billions of dollars in payments from the largest players in the nation’s drug supply chain.

And now, as their role in prescription drug pricing comes under increasing scrutiny, the nation’s biggest PBMs are changing shape again — this time by aligning themselves with the nation’s largest insurers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy